Glaxo Wellcome Ziagen
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Labeling changes have been added to black box warning, advising that additional symptoms could suggest hypersensitivity, including infectious gastroenteritis and symptoms that appear to be reactions to another medication, the firm reports in a July 27 "Dear Doctor" letter. Labeling also has been changed to state that some patients developed hypersensitivity reactions after interrupting and restarting the agent even if they did not have prior hypersensitivity. Fatal hypersensitivity has developed in two to four of every 10,000 patients who have taken Ziage
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.